Tag

Genmab A/S

1 article

J.P. Morgan Upgrades Genmab, Price Target DKr3,500

J.P. Morgan upgraded Genmab A/S to overweight from neutral and lifted its price target to DKr3,500 from DKr2,050. The firm expects petosemtamab’s November interim data to show at least 40% response, w